MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7224/1537-2073.2024-083

Медицинская библиотека · International journal of MS care · 2025

Wearing-Off Effect Reports in People With Multiple Sclerosis Receiving Ocrelizumab.

Morrow Sarah A, Gitman Victor, Sofija Spasojevic, Rassi Jessica, Pasquarelli Noemi, Fitovski Kocho, Vorobeychik Galina

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

A wearing-off effect has been reported in people with multiple sclerosis (MS) receiving ocrelizumab and other monoclonal antibodies. We sought to describe the real-world occurrence of wearing-off effect among people with MS in Canada treated with ocrelizumab.

METHODS

Canadian self-reports coded to the Medical Dictionary for Regulatory Activities preferred term therapeutic response shortened (which included reports using the terms wearing-off, crap gap, wore off, or end-of-cycle phenomenon; TRS) between November 5, 2008, and March 15, 2023, were identified from the Roche Global Safety Database. Cases were then linked to patient-level data from the Canadian Roche Patient Support Program (COMPASS). Only people with MS who had received 3 or more doses of ocrelizumab were included.

RESULTS

A total of 10,055 people with MS in Canada received 3 or more doses of ocrelizumab within COMPASS. TRS was reported 140 times among 138 unique cases (1.3%) over an average of 7.4 infusions. Discontinuation of ocrelizumab was generally uncommon. In the overall COMPASS population, 11.4% (1143 of 10,055) discontinued ocrelizumab. Among those who reported TRS, 15.9% (22 of 138) discontinued while the majority (116 of 138; 84.1%) continued ocrelizumab treatment. Of individuals reporting the adverse event of interest, those with relapsing-remitting MS more frequently remained on therapy (98 of 112; 87.5%) compared with those with primary progressive MS (18 of 26; 69.2%).

CONCLUSIONS

A wearing-off effect was infrequently reported and did not limit treatment among people with MS in the real-world COMPASS patient support program.

Для цитирования: Morrow Sarah A, Gitman Victor, Sofija Spasojevic, Rassi Jessica, Pasquarelli Noemi, Fitovski Kocho, Vorobeychik Galina. Wearing-Off Effect Reports in People With Multiple Sclerosis Receiving Ocrelizumab.. International journal of MS care. 2025. DOI: 10.7224/1537-2073.2024-083.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.